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INTRODUCTION
 Sodium glucose co-transporter 2 (SGLT2) 
inhibitors are one of the newest anti-diabetic 
drugs that improve glycemic control by increasing 
urinary excretion of glucose. SGLT2 inhibitors are 
indicated for type 2 diabetics as adjunct to diet and 
exercise. They improve weight and blood pressure 
as well with glucosuria. Since the launch of the 
medication, several cases of diabetes ketoacidosis 
(DKA) have emerged. We present a case of type 1 
diabetic patient treated with SGLT2 inhibitor who 
was admitted to the hospital with DKA. Literature 
review shows since the approval of drug class in 
2013, these drugs increase risk for DKA. The risk 
is higher in autoimmune diabetes. In May 2015, the 
Food and Drug Administration issued a warning 
that SGLT2 inhibitors may lead to ketoacidosis.
METHOD
 A literature search was conducted on the Clin-
Alert database for adverse reactions and PubMed 
using keywords ‘SGLT2’; ‘canagliflozin’ and 
‘ketoacidosis’. Results revealed two cases where 
ketoacidosis was seen in Type 2 diabetics after 
they were started on an SGLT-2 Inhibtor.1 Possible 
mechanism behind the euglycemic ketoacidosis 
was also identified.2 We hope that writing this 
case report may highlight this potential side 
effect in Type 1 Diabetics as well. Our case report 
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Case Report
Euglycemic Diabetic Ketoacidosis in a 27 year-old female 
patient with type-1-Diabetes treated with sodium-glucose 
cotransporter-2 (SGLT2) inhibitor Canagliflozin
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ABSTRACT
We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient 
treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin. The clinical history, physical 
examination findings and laboratory values are described. Other causes of acidosis such as salicylate toxicity 
or alcohol intoxication were excluded. Ketoacidosis resolved after increasing dextrose and insulin doses 
supporting the hypothesis that SGLT-2 inhibitors may lead to hypoinsulinemia. Euglycemic ketoacidosis did 
not recur in our patient after discontinuing canagliflozin. We recommend reserving SGLT2 inhibitor therapy 
to type 2 diabetics, discontinuing medication and treating patients presenting with ketoacidosis due to 
SGLT-2 inhibitors with higher concentrations of dextrose with appropriate doses of insulin to help resolve 
acidosis. 
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Euglycemic Diabetic Ketoacidosis 
features a young woman with type 1 diabetes who 
developed ketoacidosis eight months after starting 
canagliflozin.
CASE REPORT
 A 27-year-old Caucasian woman with type 
1 diabetes was admitted to the hospital with 
ketoacidosis. She was first diagnosed with type 
1-diabetes 15 years ago. She was using an insulin 
pump since age 18. Past medical history was 
significant for primary hypothyroidism and 
depression. She was started on sodium-glucose 
cotransporter-2 (SGLT2) inhibitor canaglifozin 8 
months earlier by Endocrinologist. After starting 
treatment with canaglifozin her insulin requirement 
went down. She lost about four pounds of weight 
and her hemoglobin A1C improved slightly from 
8.6% to 8.4% six months after starting canagliflozin. 
The day before presentation she worked the night 
shift, slept all day the next day and woke up at 5:00 
p.m. She felt nauseated with heavy breathing and 
muscular pains. She also noticed spots in her vision. 
Her blood sugar was normal at 114 mg/dl. She had 
eaten a grilled cheese sandwich before going to sleep 
along with two beers. No history of aspirin use. She 
worked as a nurse and drank alcohol only three 
to four times a year. There was a positive family 
history for autoimmune hypothyroidism in her 
mother. She had no known drug allergies and her 
home medications included Dexvenlafaxine 50mg 
orally for depression at bedtime and Levothyroxine 
150mcg orally once daily for hypothyroidism.
 She was treated with intravenous 5% Dextrose 
with half normal saline and insulin in the 
emergency room before being transferred to the 
Intensive care unit, but the anion gap didn’t close 
despite  continued intravenous 5% Dextrose and 
insulin administration 24 hours later. At this 
point Endocrinology services were consulted. 
She was found to be in overall stable condition. 
Her Temperature was 36.8 degrees centigrade, 
pulse was 72 beats per minute, respiratory rate was 
16, Blood pressure 131/73 and pulse ox was 98% 
on room air. She was awake and in no distress. 
Physical examination was unremarkable.
Laboratories Studies: Sodium 134, potassium 3.9, 
chloride 110, CO2 12, glucose 132mg/dl, calcium 
8.2mg/dl, TSH 0.92 with free T4 of 0.99. Anion gap 
was 16, which was improved from 20 on admission, 
but had not changed in the last 24 hours. Beta 
hydroxybutyrate were positive. Corticotrophin 
stimulation test ruled out adrenal insufficiency and 
serum salicylate levels were not high. Toxicology 
screen was negative for alcohol or other commonly 
abused illicit drugs.
 Canagliflozin use was suspected as a likely reason 
for development of resistant and unusual diabetes 
ketoacidosis episode in this patient. High fat meal 
and use of alcohol were linked to triggering of this 
episode. We recommended increasing dextrose 
infusion to 10% to help expedite removal of beta 
hydroxybutyrate. By next morning her anion gap 
closed, she felt better and she was discharged home. 
She stayed off of SGLT2 inhibitor and didn’t have 
any further episodes of euglycemic ketoacidosis.
DISCUSSION
 Sodium glucose transporters -2 (SGLT-2) inhibi-
tors have recently emerged as a novel way to treat 
diabetes and improve glycemic control. Canagli-
flozin was the first drug in this class approved by 
the Food and Drug Administration (FDA) in March 
2013.3 SGLTs are a family of sodium glucose co-
transporters. SGLT-2 is present almost exclusively 
in brush border of epithelial cells in the proximal 
tubule of the kidney. It is responsible for reabsorb-
ing around 90% of filtered glucose. SGLT-2 inhibi-
tors exploit this phenomenon by antagonizing the 
transporter.4 This leads to increased glucose excre-
tion, improving glycemic control.5 While the use of 
SGLT-2 inhibitors in Type 2 diabetics has been ex-
tensively studied both as a single agent and in com-
bination in terms of efficacy and safety,6-10 several 
independent smaller studies have shown benefit in 
Type 1 Diabetics as well.11,12 Our clinical experience 
in treating a patient with Type 1 diabetes resulted 
in an unexpected side effect – euglycemic diabetic 
ketoacidosis.
 Diabetic ketoacidosis (DKA) is a life threatening 
condition characterized by uncontrolled hypergly-
cemia, increased levels of ketones and metabolic ac-
idosis. DKA is much less commonly seen in type 2 
diabetes as compared to type 1 diabetics. The mech-
anism behind DKA is hormonal derangements 
between insulin and other counter regulatory hor-
mones like glucagon, cortisol, growth hormone and 
catecholamines.13 In the case of our type 1 diabetic 
patient, glucose levels were normal suggesting this 
was an atypical case of DKA.
  SGLT-2 inhibitors help improve glycemic control 
in diabetic patients by preventing renal glucose 
re-absorption as mentioned earlier in the paper. 
However, treatment in subjects with type 2 diabetes 
increases both plasma glucagon and endogenous 
glucose production, which may be the cause behind 
the normoglycemia during atypical DKA. Biological 
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research on this factor has mostly focused on islet 
cells of Type 2 diabetics.  
 The exact mechanisms are unknown at present 
time. In a recently published study in Nature, it is 
demonstrated that SGLT2 is expressed in glucagon-
secreting alpha cells of the pancreatic islets.14 The 
investigators further found that expression of 
SLC5A2 (which encodes SGLT2) was lower and 
glucagon (GCG) gene expression was higher in islets 
from type 2 diabetic individuals and in normal islets 
exposed to chronic hyperglycemia than in islets 
from non-diabetics. In addition SGLT-2 inhibitor 
treatment in human islets triggered glucagon 
secretion through KATP channel activation. 
The investigators also found that dapagliflozin 
treatment further promotes glucagon secretion and 
hepatic gluconeogenesis in healthy mice, thereby 
limiting the decrease of plasma glucose induced by 
fasting. This may be a possible mechanism behind 
the masking of hyperglycemia in this patient.
CONCLUSIONS
 SGLT2 inhibitors are an exciting new drug class 
that is safe and efficient in most type 2 diabetes 
patients. SGLT2 inhibitors can cause DKA in both 
type 1 and type 2 diabetes. Patients and healthcare 
providers need to be educated on signs and 
symptoms of DKA associated with SGLT2 inhibitors 
for reducing patient morbidity and mortality.
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